12/15/2008

Novartis AG reported preliminary data from a late-stage trial showing that 0.5 mg and 1.25 mg doses of FTY720, a drug candidate for multiple sclerosis, were more effective in reducing relapse than Avonex, an injectable drug from Biogen Idec. Novartis said it may seek FDA approval for FTY720 at the end of next year.

Related Summaries